Purpose SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with
traditional risk factors to individualize risk prediction for clinically significant prostate cancer …

Objective To assess the cost‐effectiveness of a new urinary biomarker‐based risk score
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …

Purpose: We performed a cost-effectiveness analysis using the PHI (Prostate Health Index),
4Kscore®, SelectMDx™ and the EPI (ExoDx™ Prostate [IntelliScore]) in men with elevated …

Introduction: There is an unmet need for noninvasive methods to better identify patients at
increased risk for clinically significant prostate cancer. SelectMDx® is a molecular urine test …

At every point along the prostate cancer continuum of care, from early detection through to
advanced disease, a man must face decisions that may have a direct impact on his long …

Simple Summary PCa remains a leading health concern worldwide. Serum PSA-based PCa
screening led to a well-documented decreased mortality but at the cost of the increased …

Historically, prostate biopsy was performed because of a prostate-specific antigen (PSA)
level exceeding a specific threshold or suspicious findings on digital rectal examination …

Background. New cancer biomarkers are being discovered at a rapid pace; however, these
tests vary in their predictive performance characteristics, and it is unclear how best to use …

Prostate cancer is a heterogeneous disease with disparate outcomes. Traditional clinical
parameters are limited in their ability to differentiate between these cases, and there is …

Prostate cancer screening and diagnosis has been guided by prostate-specific antigen
levels for the past 25 years, but with the most recent US Preventive Services Task Force …